Your browser doesn't support javascript.
loading
Scale-up of the DMPA-SC in Nigeria: Why policy matters.
Akinyemi, Oluwaseun; Danfakha, Nicole; Adefalu, Adewole; Easley, Ebony; Afolabi, Kayode; Latunji, Olajimi.
Afiliação
  • Akinyemi O; Department of Health Policy and Management, College of Medicine, University of Ibadan, Ibadan, Nigeria. seunakinyemi@hotmail.com.
  • Danfakha N; John Snow Inc., Capitol Heights, MD, USA.
  • Adefalu A; John Snow Inc., Abuja, Nigeria.
  • Easley E; John Snow Inc., Philadelphia, PA, USA.
  • Afolabi K; Federal Ministry of Health, Abuja, Nigeria.
  • Latunji O; John Snow Inc., Abuja, Nigeria.
BMC Womens Health ; 22(1): 535, 2022 12 21.
Article em En | MEDLINE | ID: mdl-36544189
BACKGROUND: Injectable contraceptives have contributed substantially to Nigeria's rise in modern family planning methods usage. They are one of the most commonly used and preferred means of contraception among women in the country. Enabling policies are required to assure contraceptive access, security, and use. This study aimed to investigate the policy environment and how it supports or limits Nigeria's introduction and scale-up of subcutaneous depot-medroxyprogesterone acetate (DMPA-SC). METHODS: The design of this mixed-methods study was cross-sectional. Desk reviews of policy papers, key informant interviews, and in-depth interviews were used to obtain information from respondents about the introduction of DMPA-SC in Nigeria and how existing policies influenced its scale-up. Data on DMPA-SC and other injectables were gathered from Nigeria's national electronic logistics management information system. RESULTS: The findings suggest that policies such as task-shifting and task-sharing, cost-free policies, reproductive health policies, and others created an enabling environment for the scale-up of DMPA-SC adoption in Nigeria. The inclusion of DMPA-SC on the essential medicines list and the approved patent medicines list facilitated the scale-up process by ensuring private sector participation, removing economic barriers to access, fostering greater collaboration among health worker cadres, improving intersectoral partnerships, and improving logistics and client access. Despite significant anomalies in some implementing policies, injectable contraceptive consumption data demonstrate a progressive increase in DMPA-SC use during the study period. The results also indicate that policy initiatives have a favorable impact on the use of DMPA-SC throughout the country. CONCLUSION: The existence of policies, the active participation of stakeholders, and the political will of the Nigerian health system's leadership have all aided in the scaling-up of the DMPA-SC. Understanding how to build an enabling policy climate is critical for providing women with family planning options. These lessons from Nigeria emphasize the importance of these levers, which should be considered by teams intending to introduce innovative health products, particularly in developing countries.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acetato de Medroxiprogesterona / Anticoncepcionais Femininos Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Female / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Acetato de Medroxiprogesterona / Anticoncepcionais Femininos Tipo de estudo: Observational_studies / Prevalence_studies / Prognostic_studies / Qualitative_research / Risk_factors_studies Limite: Female / Humans País/Região como assunto: Africa Idioma: En Ano de publicação: 2022 Tipo de documento: Article